Pacira Pharmaceuticals Director Sells $5,609,898 in Stock (PCRX)
Pacira Pharmaceuticals (NASDAQ:PCRX) Director Andreas Wicki sold 67,900 shares of the company’s stock in a transaction that occurred on Friday, June 6th. The shares were sold at an average price of $82.62, for a total value of $5,609,898.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Shares of Pacira Pharmaceuticals (NASDAQ:PCRX) traded up 1.38% during mid-day trading on Friday, hitting $83.67. 644,827 shares of the company’s stock traded hands. Pacira Pharmaceuticals has a 52 week low of $26.72 and a 52 week high of $83.92. The stock has a 50-day moving average of $74.80 and a 200-day moving average of $66.43. The company’s market cap is $2.983 billion.
Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its earnings results on Thursday, May 1st. The company reported ($0.19) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.32) by $0.13. The company had revenue of $36.70 million for the quarter, compared to the consensus estimate of $35.40 million. The company’s quarterly revenue was up 216.4% on a year-over-year basis. On average, analysts predict that Pacira Pharmaceuticals will post $-0.57 earnings per share for the current fiscal year.
A number of research firms have recently commented on PCRX. Analysts at Goldman Sachs initiated coverage on shares of Pacira Pharmaceuticals in a research note on Monday. They set a “buy” rating and a $93.00 price target on the stock. Separately, analysts at Jefferies Group reiterated a “buy” rating on shares of Pacira Pharmaceuticals in a research note on Thursday, May 15th. They now have a $81.00 price target on the stock. Finally, analysts at Jefferies Group reiterated a “buy” rating on shares of Pacira Pharmaceuticals in a research note on Wednesday, May 7th. They now have a $81.00 price target on the stock. Eight research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and a consensus target price of $77.92.
Pacira Pharmaceuticals, Inc is a United States-based pharmaceutical company. The Company develops non-opioid products for postsurgical pain control.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.